Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYNJ2 | O15056 | 3/20 | 0.87 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.49 |
| ▸ | GRK2 | P25098 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.35 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.35 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Albiflorin SCHEMBL21164770 | 1.00 | SYNJ2 (0.87) | SYNJ2SLC22A1GRK2MAOBPTPN1 | |
| Albiflorin SCHEMBL21315817 | 1.00 | SYNJ2 (0.87) | SYNJ2SLC22A1GRK2MAOBPTPN1 | |
| Albiflorin SCHEMBL623462 | 1.00 | SYNJ2 (0.87) | SYNJ2SLC22A1GRK2MAOBPTPN1 | |
| Albiflorin SCHEMBL15235363 | 1.00 | SYNJ2 (0.87) | SYNJ2SLC22A1GRK2MAOBPTPN1 | |
| Albiflorin SCHEMBL29500192 | 1.00 | SYNJ2 (0.87) | SYNJ2SLC22A1GRK2MAOBPTPN1 | |
| Albiflorin SCHEMBL24008597 | 1.00 | SYNJ2 (0.87) | SYNJ2SLC22A1GRK2MAOBPTPN1 | |
| Albiflorin SCHEMBL21702839 | 1.00 | SYNJ2 (0.87) | SYNJ2SLC22A1GRK2MAOBPTPN1 | |
| Albiflorin SCHEMBL13387630 | 0.98 | SYNJ2 (0.85) | SYNJ2SLC22A1GRK2MAOBPTPN1 | |
| SCHEMBL21325290 | 0.94 | SYNJ2 (0.77) | SYNJ2SLC22A1GRK2MAOBPTPN1 | |
| Paeonivayin SCHEMBL18504853 | 0.93 | SYNJ2 (1.00) | SYNJ2SLC22A1GRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200352842-A1 | COMPOSITION FOR PREVENTING OR IMPROVING INTRINSIC AGING COMPRISING PAEONIFLORIN OR ALBIFLORIN | AMOREPACIFIC CORPORATION (KR) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352842-A1 | COMPOSITION FOR PREVENTING OR IMPROVING INTRINSIC AGING COMPRISING PAEONIFLORIN OR ALBIFLORIN | GLA, ATG13, ALB | SYNJ2 1185/4885SLC22A1 3499/4885GRK2 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.